Literature DB >> 16890732

A selective alpha1A-adrenoceptor antagonist inhibits detrusor overactivity in a rat model of benign prostatic hyperplasia.

Satoshi Tatemichi1, Katsuyoshi Akiyama, Mamoru Kobayashi, Yoshinobu Yamazaki, Osamu Yokoyama, Tsutomu Uruno.   

Abstract

PURPOSE: Alpha(1)-adrenoceptor antagonists relax the obstructed prostatic urethra and suppress the irritative symptoms frequently observed in patients with benign prostatic hyperplasia. We investigated the effects of 3 alpha(1)-adrenoceptor antagonists on urodynamics in rats with hormone induced benign prostatic hyperplasia to determine which alpha(1)-adrenoceptor subtype selective antagonists would suppress irritative symptoms.
MATERIALS AND METHODS: Rats were treated with testosterone and 17beta-estradiol by weekly intramuscular injections. After 4 weeks a pressure flow study was done and the effects of the alpha(1)-adrenoceptor antagonists KMD-3213 silodosin, tamsulosin and prazosin on urodynamics were compared. We especially investigated the involvement of the bladder and prostatic urethra to clarify the mechanism of detrusor overactivity expression.
RESULTS: Hormone treatment induced benign prostatic hyperplasia and resulted in detrusor overactivity, as determined by cystometry. Baseline perfusion urethral pressure and the phenylephrine induced increase in it were significantly higher in rats with vs without benign prostatic hyperplasia. Cystometry in hormone treated female rats did not show detrusor overactivity. KMD-3213 decreased detrusor overactivity, similar to other alpha(1)-adrenoceptor antagonists.
CONCLUSIONS: These results suggest that an excessive response to sympathetic nerve stimulation, which is mainly mediated via alpha(1A)-adrenoceptor, in the hypertrophied prostate gives rise to detrusor overactivity. Furthermore, the alpha(1A)-adrenoceptor selective antagonist KMD-3213 would be suitable for improving irritative symptoms in patients with benign prostatic hyperplasia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16890732     DOI: 10.1016/j.juro.2006.04.029

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  5 in total

1.  Impact of a folic acid-enriched diet on urinary tract function in mice treated with testosterone and estradiol.

Authors:  Kimberly P Keil; Lisa L Abler; Helene M Altmann; Zunyi Wang; Peiqing Wang; William A Ricke; Dale E Bjorling; Chad M Vezina
Journal:  Am J Physiol Renal Physiol       Date:  2015-04-08

2.  [New treatment strategies for male lower urinary tract symptoms].

Authors:  L F Arenas da Silva; M Schönthaler; F Cruz; C Gratzke; J Zumbe; A Stenzl; B Amend; K-D Sievert
Journal:  Urologe A       Date:  2012-12       Impact factor: 0.639

3.  Controlled release of dutasteride from biodegradable microspheres: in vitro and in vivo studies.

Authors:  Xiangyang Xie; Yanfang Yang; Qiang Chi; ZhiPing Li; Hui Zhang; Ying Li; Yang Yang
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

4.  Additive effect of oral LDD175 to tamsulosin and finasteride in a benign prostate hyperplasia rat model.

Authors:  Hye Kyung Kim; Jong Kwan Park; Bo Ram Choi; Kiran Kumar Soni; Keshab Kumar Karna; Sung Won Lee; Insuk So
Journal:  Drug Des Devel Ther       Date:  2018-06-22       Impact factor: 4.162

Review 5.  Management of benign prostatic hyperplasia with silodosin.

Authors:  Tomonori Yamanishi; Tomoya Mizuno; Takao Kamai; Ken-Ichiro Yoshida; Ryuji Sakakibara; Tomoyuki Uchiyama
Journal:  Open Access J Urol       Date:  2009-08-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.